- Home
- CLPR vs GNLX Comparison
CLPR vs GNLX Comparison
Compare CLPR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- GNLX
- Stock Information
- Founded
- CLPR 2015
- GNLX 2001
- Country
- CLPR United States
- GNLX United States
- Employees
- CLPR N/A
- GNLX N/A
- Industry
- CLPR Real Estate Investment Trusts
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- GNLX Health Care
- Exchange
- CLPR Nasdaq
- GNLX Nasdaq
- Market Cap
- CLPR 72.0M
- GNLX 184.4M
- IPO Year
- CLPR 2017
- GNLX 2023
- Fundamental
- Price
- CLPR $4.41
- GNLX $3.58
- Analyst Decision
- CLPR Sell
- GNLX Strong Buy
- Analyst Count
- CLPR 2
- GNLX 4
- Target Price
- CLPR N/A
- GNLX $18.25
- AVG Volume (30 Days)
- CLPR 71.9K
- GNLX 174.5K
- Earning Date
- CLPR 05-06-2025
- GNLX 03-31-2025
- Dividend Yield
- CLPR 8.44%
- GNLX N/A
- EPS Growth
- CLPR N/A
- GNLX N/A
- EPS
- CLPR N/A
- GNLX N/A
- Revenue
- CLPR $148,775,000.00
- GNLX $8,000.00
- Revenue This Year
- CLPR N/A
- GNLX N/A
- Revenue Next Year
- CLPR N/A
- GNLX N/A
- P/E Ratio
- CLPR N/A
- GNLX N/A
- Revenue Growth
- CLPR 7.65
- GNLX N/A
- 52 Week Low
- CLPR $3.38
- GNLX $1.60
- 52 Week High
- CLPR $7.12
- GNLX $7.04
- Technical
- Relative Strength Index (RSI)
- CLPR 49.90
- GNLX 42.56
- Support Level
- CLPR $4.21
- GNLX $3.51
- Resistance Level
- CLPR $4.61
- GNLX $4.37
- Average True Range (ATR)
- CLPR 0.23
- GNLX 0.44
- MACD
- CLPR -0.02
- GNLX -0.13
- Stochastic Oscillator
- CLPR 33.33
- GNLX 12.82
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.